PURPOSE: We address whether rational and significant clinical data exist on using angiogenic targeted therapies as neoadjuvant or adjuvant options to nephrectomy in non-metastatic RCC. METHODS: We reviewed the recent international literature by carrying out a PUBMED search. RESULTS: Neoadjuvant: a possible indication for a neoadjuvant targeted therapy approach is to facilitate surgery, reducing risks for patients and increasing the possibility of removing the mass and improving oncological results. Adjuvant: three major phase III clinical trials are currently ongoing. The ASSURE trial (1 year on oral sunitinib, sorafenib or placebo), the SORCE trial (3 years on placebo versus 1 year on sorafenib, followed by 2 years on placebo versus 3 years on sorafenib), and the S-TRAC trial (1 year on sunitinib or placebo) analyze patients who are at high risk of relapse. CONCLUSIONS: Rationale and needs for the neoadjuvant or adjuvant use of targeted therapies in RCC are relevant. Significant phase III trials on the adjuvant use of targeted therapy in RCC are ongoing.
PURPOSE: We address whether rational and significant clinical data exist on using angiogenic targeted therapies as neoadjuvant or adjuvant options to nephrectomy in non-metastatic RCC. METHODS: We reviewed the recent international literature by carrying out a PUBMED search. RESULTS: Neoadjuvant: a possible indication for a neoadjuvant targeted therapy approach is to facilitate surgery, reducing risks for patients and increasing the possibility of removing the mass and improving oncological results. Adjuvant: three major phase III clinical trials are currently ongoing. The ASSURE trial (1 year on oral sunitinib, sorafenib or placebo), the SORCE trial (3 years on placebo versus 1 year on sorafenib, followed by 2 years on placebo versus 3 years on sorafenib), and the S-TRAC trial (1 year on sunitinib or placebo) analyze patients who are at high risk of relapse. CONCLUSIONS: Rationale and needs for the neoadjuvant or adjuvant use of targeted therapies in RCC are relevant. Significant phase III trials on the adjuvant use of targeted therapy in RCC are ongoing.
Authors: Kwang Hyun Kim; Dalsan You; In Gab Jeong; Cheryn Song; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim Journal: J Cancer Res Clin Oncol Date: 2012-05-01 Impact factor: 4.553
Authors: Ronan Flippot; Roger Mouawad; Jean-Philippe Spano; Morgan Rouprêt; Eva Compérat; Marc-Olivier Bitker; Jérôme Parra; Christophe Vaessen; Frederick Allanic; Quentin Manach; Nizar M Tannir; David Khayat; Xiaoping Su; Gabriel G Malouf Journal: Sci Rep Date: 2017-08-17 Impact factor: 4.379